Raymond J Cho, MD
Dermatology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 5
- Since medical school
- 21 years
- Stanford University School of Medicine, 2005
Offices
5 locations · University of California San Francisco · UCSF Medical Group Business Services
Looking this up.
Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Cho’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A96916 · Current
Licensed to practise in California · since 2006 · expires 2028-04-30 · Stanford University School of Medicine.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$74,218
Medicare paid this office $74,218 for 357 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 189 | $25,963 | $82 |
| Short return visit (20+ min) | 151 | $9,881 | $51 |
| Destruction of precancer skin growth, 1 growth | 147 | $7,671 | $39 |
| Destruction of skin growth, 1-14 growths | 98 | $7,390 | $64 |
| New patient visit (45+ min) | 52 | $5,043 | $97 |
See all 14 services
| Return visit (30+ min) | 189 | $25,963 | $82 |
| Short return visit (20+ min) | 151 | $9,881 | $51 |
| Destruction of precancer skin growth, 1 growth | 147 | $7,671 | $39 |
| Destruction of skin growth, 1-14 growths | 98 | $7,390 | $64 |
| New patient visit (45+ min) | 52 | $5,043 | $97 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 16 | $2,779 | $154 |
| Biopsy of related skin growth, first growth | 74 | $2,195 | $23 |
| New patient visit (30+ min) | 30 | $1,963 | $65 |
| Punch biopsy, first skin growth | 41 | $1,294 | $28 |
| Destruction of precancer skin growth, 2-14 growths | 121 | $877 | $2 |
| Short return visit | 23 | $705 | $29 |
| Biopsy of related skin growth, each additional growth | 24 | $690 | $19 |
| Online digital evaluation and management service for an established patient for up to 7 days, total time 5-10 minutes | 41 | $521 | $11 |
| Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | 11 | $345 | $25 |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 20 | More than 74% of doctors who do this |
| Removal of skin lesions | 380 | More than 84% of doctors who do this |
| Removal or shaving of skin growth | 36 | More than 76% of doctors who do this |
| Skin biopsy | 129 | More than 79% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 443 | 666 | 822 | 900 | 713 | 508 |
| Destruction of precancer skin growth, 1 growth | 202 | 222 | 213 | 229 | 231 | 196 |
| Destruction of skin growth, 1-14 growths | 59 | 66 | 80 | 116 | 140 | 116 |
| Biopsy of related skin growth, first growth | 58 | 79 | 75 | 91 | 108 | 94 |
| Punch biopsy, first skin growth | 54 | 64 | 43 | 62 | 70 | 46 |
| Biopsy of related skin growth, each additional growth | 26 | 25 | 19 | 23 | 37 | 37 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
357 Original Medicare patients in 2024. Average age 75 · Under 65 9% · 85 and older 15% · Women 50% · Also on Medicaid 31% · Health risk score 1.28. Above the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 63% · Diabetes 24% · Coronary heart disease 20% · Chronic kidney disease 19% · Cancer 18% · Depression 18% · Atrial fibrillation 15% · COPD 12% · Heart failure 11% · Stroke 7% · Dementia 5%.
The office billed $789,358, Medicare allowed $101,997 and paid $74,218; for 1,795 services of 46 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 357 | 1,795 | 75 | 1.28 | $789,358 | $74,218 |
| 2023 | 344 | 2,049 | 74 | 1.32 | $809,745 | $71,431 |
| 2022 | 364 | 2,139 | 73 | 1.34 | $763,743 | $68,573 |
| 2021 | 306 | 1,867 | 73 | 1.32 | $611,402 | $55,306 |
| 2020 | 290 | 1,872 | 73 | 1.25 | $640,456 | $51,343 |
| 2019 | 328 | 1,467 | 73 | 1.36 | $525,749 | $44,790 |
| 2018 | 314 | 1,391 | 73 | 1.34 | $435,161 | $38,005 |
| 2017 | 278 | 1,082 | 71 | 1.48 | $338,027 | $32,085 |
| 2016 | 264 | 1,135 | 72 | 1.40 | $321,046 | $29,779 |
| 2015 | 310 | 1,175 | 72 | 1.47 | $323,590 | $30,587 |
| 2014 | 333 | 1,457 | 70 | 1.36 | $369,346 | $35,530 |
| 2013 | 343 | 1,731 | 71 | 1.41 | $378,740 | $40,844 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 14 services
| Return visit (30+ min) | 170 | $18,624 | $78 |
| Short return visit (20+ min) | 162 | $11,863 | $52 |
| Destruction of precancer skin growth, 1 growth | 156 | $8,439 | $37 |
| Destruction of skin growth, 1-14 growths | 106 | $8,104 | $58 |
| New patient visit (45+ min) | 40 | $4,009 | $100 |
| New patient visit (30+ min) | 50 | $3,011 | $60 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 15 | $2,571 | $161 |
| Biopsy of related skin growth, first growth | 88 | $2,261 | $21 |
| Punch biopsy, first skin growth | 61 | $2,156 | $31 |
| Destruction of precancer skin growth, 2-14 growths | 128 | $1,142 | $2 |
| Short return visit | 23 | $857 | $31 |
| Biopsy of related skin growth, each additional growth | 31 | $670 | $18 |
| Punch biopsy, each additional skin growth | 15 | $460 | $22 |
| Online digital evaluation and management service for an established patient for up to 7 days, total time 5-10 minutes | 32 | $358 | $10 |
2022: 13 services
| Return visit (30+ min) | 152 | $18,163 | $81 |
| Short return visit (20+ min) | 173 | $11,493 | $51 |
| Destruction of precancer skin growth, 1 growth | 158 | $8,625 | $38 |
| Destruction of skin growth, 1-14 growths | 100 | $6,388 | $55 |
| New patient visit (45+ min) | 43 | $4,930 | $115 |
| New patient visit (30+ min) | 50 | $3,209 | $64 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 19 | $3,070 | $146 |
| Punch biopsy, first skin growth | 58 | $1,740 | $28 |
| Biopsy of related skin growth, first growth | 75 | $1,612 | $18 |
| Destruction of precancer skin growth, 2-14 growths | 134 | $1,518 | $2 |
| Short return visit | 24 | $821 | $27 |
| Biopsy of related skin growth, each additional growth | 13 | $453 | $20 |
| Online digital evaluation and management service for an established patient for up to 7 days, total time 5-10 minutes | 27 | $324 | $10 |
2021: 14 services
| Return visit (30+ min) | 101 | $12,244 | $83 |
| Short return visit (20+ min) | 153 | $10,828 | $51 |
| Destruction of precancer skin growth, 1 growth | 136 | $7,797 | $37 |
| Destruction of skin growth, 1-14 growths | 64 | $4,052 | $51 |
| New patient visit (45+ min) | 36 | $3,825 | $106 |
| New patient visit (30+ min) | 38 | $2,321 | $61 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 11 | $2,066 | $159 |
| Short return visit | 40 | $1,557 | $31 |
| Biopsy of related skin growth, first growth | 68 | $1,442 | $19 |
| Destruction of precancer skin growth, 2-14 growths | 124 | $1,347 | $2 |
| Punch biopsy, first skin growth | 41 | $1,183 | $28 |
| Strapping, unna boot | 16 | $819 | $22 |
| New patient visit (15+ min) | 16 | $576 | $36 |
| Biopsy of related skin growth, each additional growth | 15 | $301 | $16 |
2020: 12 services
| Short return visit (20+ min) | 221 | $18,318 | $40 |
| Destruction of precancer skin growth, 1 growth | 137 | $8,413 | $38 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 22 | $3,778 | $164 |
| Destruction of skin growth, 1-14 growths | 54 | $3,671 | $56 |
| New patient visit (30+ min) | 46 | $2,325 | $51 |
| Punch biopsy, first skin growth | 58 | $1,806 | $28 |
| Biopsy of related skin growth, first growth | 66 | $1,392 | $18 |
| Destruction of precancer skin growth, 2-14 growths | 112 | $1,138 | $2 |
| New patient visit (15+ min) | 31 | $1,040 | $34 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 13 | $924 | $71 |
| Short return visit | 30 | $830 | $21 |
| Biopsy of related skin growth, each additional growth | 22 | $438 | $18 |
2019: 11 services
| Short return visit (20+ min) | 224 | $14,316 | $40 |
| Destruction of precancer skin growth, 1 growth | 142 | $7,941 | $39 |
| Destruction of skin growth, 1-14 growths | 47 | $3,626 | $61 |
| New patient visit (30+ min) | 52 | $3,340 | $64 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 12 | $2,255 | $173 |
| New patient visit (15+ min) | 51 | $2,009 | $39 |
| Punch biopsy, first skin growth | 53 | $1,705 | $32 |
| Biopsy of related skin growth, first growth | 48 | $1,273 | $22 |
| Short return visit | 39 | $1,045 | $20 |
| Destruction of precancer skin growth, 2-14 growths | 103 | $782 | $2 |
| Biopsy of related skin growth, each additional growth | 18 | $527 | $20 |
2018: 9 services
| Short return visit (20+ min) | 208 | $12,548 | $39 |
| Destruction of precancer skin growth, 1 growth | 121 | $8,102 | $42 |
| New patient visit (15+ min) | 90 | $3,481 | $39 |
| Biopsy of single growth of skin and/or tissue | 97 | $3,130 | $27 |
| Destruction of skin growth, 1-14 growths | 34 | $2,980 | $57 |
| Short return visit | 48 | $1,510 | $20 |
| Destruction of precancer skin growth, 2-14 growths | 88 | $850 | $2 |
| New patient visit (30+ min) | 11 | $588 | $53 |
| Biopsy of each additional growth of skin and/or tissue | 11 | $262 | $20 |
2017: 7 services
| Short return visit (20+ min) | 178 | $11,362 | $41 |
| Destruction of precancer skin growth, 1 growth | 113 | $7,129 | $43 |
| New patient visit (15+ min) | 71 | $2,680 | $38 |
| Biopsy of single growth of skin and/or tissue | 76 | $2,107 | $26 |
| Short return visit | 49 | $1,111 | $21 |
| Destruction of skin growth, 1-14 growths | 15 | $1,062 | $59 |
| Destruction of precancer skin growth, 2-14 growths | 87 | $655 | $2 |
2016: 7 services
| Short return visit (20+ min) | 178 | $10,623 | $41 |
| Destruction of precancer skin growth, 1 growth | 111 | $7,266 | $42 |
| New patient visit (15+ min) | 73 | $2,557 | $35 |
| Biopsy of single growth of skin and/or tissue | 65 | $2,017 | $28 |
| Destruction of skin growth, 1-14 growths | 22 | $1,373 | $60 |
| Short return visit | 50 | $1,193 | $21 |
| Destruction of precancer skin growth, 2-14 growths | 81 | $723 | $2 |
2015: 6 services
| Short return visit (20+ min) | 173 | $9,738 | $40 |
| Destruction of precancer skin growth, 1 growth | 107 | $7,470 | $45 |
| New patient visit (15+ min) | 91 | $3,249 | $36 |
| Biopsy of single growth of skin and/or tissue | 83 | $2,819 | $30 |
| Short return visit | 57 | $1,486 | $21 |
| Destruction of precancer skin growth, 2-14 growths | 76 | $799 | $2 |
2014: 8 services
| Short return visit (20+ min) | 210 | $12,700 | $41 |
| Destruction of precancer skin growth, 1 growth | 109 | $7,437 | $44 |
| New patient visit (15+ min) | 103 | $3,970 | $39 |
| Biopsy of single growth of skin and/or tissue | 98 | $2,961 | $28 |
| Short return visit | 61 | $1,522 | $20 |
| Destruction of precancer skin growth, 2-14 growths | 88 | $1,149 | $2 |
| Destruction of skin growth, 1-14 growths | 12 | $1,078 | $67 |
| Biopsy of each additional growth of skin and/or tissue | 15 | $400 | $20 |
2013: 9 services
| Short return visit (20+ min) | 198 | $11,030 | $39 |
| Destruction of precancer skin growth, 1 growth | 114 | $8,916 | $48 |
| New patient visit (15+ min) | 98 | $3,749 | $38 |
| Biopsy of single growth of skin and/or tissue | 103 | $3,370 | $30 |
| Destruction of precancer skin growth, 2-14 growths | 92 | $3,146 | $4 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 13 | $2,588 | $185 |
| Short return visit | 78 | $1,943 | $20 |
| Destruction of skin growth, 1-14 growths | 13 | $1,384 | $60 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 17 | $126 | $7 |
Medicaid work
$11,395 in 2024
Medicaid paid $11,395 for 87 billed services this clinician did in 2024, up to 17 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 87 | $11,395 |
| 2024 | 87 | 1 | 17 | $11,395 |
| 2023 | 59 | 2 | 17 | $4,771 |
| 2022 | 39 | 2 | 13 | $1,279 |
| 2021 | 27 | 1 | 13 | $2,040 |
| 2020 | 160 | 3 | 20 | $5,210 |
| 2019 | 104 | 3 | 17 | $2,538 |
| 2018 | 72 | 2 | 17 | $1,217 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 45 | $4,692 |
| Hospital outpatient clinic visit for assessment and management of a patient | 14 | $79 |
2022
| Return visit (30+ min) | 13 | $931 |
| Hospital outpatient clinic visit for assessment and management of a patient | 26 | $347 |
2021
| Return visit (30+ min) | 27 | $2,040 |
2020
| Short return visit (20+ min) | 134 | $4,956 |
| Hospital outpatient clinic visit for assessment and management of a patient | 13 | $216 |
| Telehealth transmission, per minute, professional services bill separately | 13 | $38 |
2019
| Short return visit (20+ min) | 65 | $2,138 |
| OFF/OP EST MAY X REQ PHY/QHP | 12 | $399 |
| Hospital outpatient clinic visit for assessment and management of a patient | 27 | $0 |
2018
| Short return visit (20+ min) | 57 | $1,217 |
| Hospital outpatient clinic visit for assessment and management of a patient | 15 | $0 |
Drugs they prescribed that Part D paid
$630,608
Pharmacies billed $630,608 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
646 generic and 137 brand-name prescriptions · $630,608 in drug cost · 46 antibiotic prescriptions to 30 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Remicade | 16 | $205,854 | $12,866 |
| Dupixent | 35 | $129,119 | $3,689 |
| Cosentyx Unoready | 12 | $106,097 | $8,841 |
| Dupixent | 18 | $73,116 | $4,062 |
| Calcipotriene | 45 | $4,504 | $100 |
See all 20 drugs
| Remicade | 16 | $205,854 | $12,866 |
| Dupixent | 35 | $129,119 | $3,689 |
| Cosentyx Unoready | 12 | $106,097 | $8,841 |
| Dupixent | 18 | $73,116 | $4,062 |
| Calcipotriene | 45 | $4,504 | $100 |
| Fluorouracil | 67 | $3,667 | $55 |
| Fluocinonide | 61 | $2,579 | $42 |
| Doxepin | 13 | $2,231 | $172 |
| Clobetasol Propionate | 35 | $1,784 | $51 |
| Triamcinolone Acetonide | 83 | $1,244 | $15 |
| Doxycycline Hyclate | 41 | $978 | $24 |
| Minoxidil | 48 | $570 | $12 |
| Econazole Nitrate | 19 | $405 | $21 |
| Clindamycin Phosphate | 11 | $294 | $27 |
| Ketoconazole | 22 | $286 | $13 |
| Methotrexate | 22 | $224 | $10 |
| Hydrocortisone | 46 | $164 | $4 |
| Mupirocin | 23 | $152 | $7 |
| Terbinafine | 24 | $110 | $5 |
| Sodium Chloride | 15 | $42 | $3 |
Year by year
| 2024 | 783 | 235 | None | 17% | $630,608 |
| 2023 | 722 | 235 | 0% (0) | 13% | $452,075 |
| 2022 | 615 | 226 | 0% (0) | 7% | $209,524 |
| 2021 | 459 | 174 | 0% (0) | 13% | $280,070 |
| 2020 | 471 | 181 | 0% (0) | 11% | $163,706 |
| 2019 | 434 | 164 | None | 10% | $38,563 |
| 2018 | 391 | 160 | None | 9% | $44,798 |
| 2017 | 345 | 123 | 0% (0) | 12% | $37,444 |
| 2016 | 387 | 138 | 0% (0) | 7% | $31,667 |
| 2015 | 483 | 158 | 0% (0) | 14% | $41,451 |
| 2014 | 370 | 163 | 0% (0) | 16% | $49,754 |
| 2013 | 368 | 167 | None | 11% | $19,375 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 16 drugs
| Dupixent | 42 | $184,781 | $4,400 |
| Remicade | 11 | $100,398 | $9,127 |
| Dupixent | 15 | $55,715 | $3,714 |
| Calcipotriene | 44 | $7,567 | $172 |
| Fluorouracil | 65 | $5,785 | $89 |
| Fluocinonide | 60 | $3,785 | $63 |
| Clobetasol Propionate | 33 | $3,596 | $109 |
| Doxycycline Hyclate | 37 | $1,635 | $44 |
| Triamcinolone Acetonide | 65 | $1,546 | $24 |
| Minoxidil | 72 | $991 | $14 |
| Lidocaine | 18 | $870 | $48 |
| Desonide | 12 | $539 | $45 |
| Ketoconazole | 18 | $348 | $19 |
| Clindamycin Phosphate | 11 | $324 | $29 |
| Hydrocortisone | 48 | $296 | $6 |
| Mupirocin | 20 | $256 | $13 |
2022: 14 drugs
| Dupixent | 17 | $110,188 | $6,482 |
| Tacrolimus | 17 | $5,912 | $348 |
| Calcipotriene | 27 | $4,712 | $175 |
| Fluorouracil | 54 | $4,609 | $85 |
| Lidocaine | 28 | $3,740 | $134 |
| Fluocinonide | 46 | $2,657 | $58 |
| Econazole Nitrate | 18 | $2,537 | $141 |
| Triamcinolone Acetonide | 118 | $2,368 | $20 |
| Clobetasol Propionate | 25 | $2,254 | $90 |
| Doxycycline Hyclate | 30 | $1,350 | $45 |
| Hydrocortisone | 45 | $308 | $7 |
| Terbinafine | 11 | $219 | $20 |
| Minoxidil | 16 | $139 | $9 |
| Mupirocin | 14 | $100 | $7 |
2021: 10 drugs
| Dupixent | 27 | $100,257 | $3,713 |
| Humira(Cf) | 13 | $72,880 | $5,606 |
| Fluorouracil | 41 | $5,059 | $123 |
| Fluocinonide | 46 | $2,709 | $59 |
| Triamcinolone Acetonide | 95 | $1,990 | $21 |
| Doxycycline Hyclate | 21 | $1,112 | $53 |
| Clobetasol Propionate | 12 | $935 | $78 |
| Lidocaine | 14 | $469 | $33 |
| Hydrocortisone | 16 | $88 | $6 |
| Mupirocin | 15 | $80 | $5 |
2020: 8 drugs
| Dupixent | 33 | $104,832 | $3,177 |
| Fluorouracil | 36 | $4,084 | $113 |
| Clobetasol Propionate | 33 | $3,747 | $114 |
| Fluocinonide | 60 | $3,741 | $62 |
| Triamcinolone Acetonide | 98 | $2,606 | $27 |
| Doxycycline Hyclate | 34 | $1,035 | $30 |
| Econazole Nitrate | 11 | $404 | $37 |
| Hydroxyzine | 19 | $403 | $21 |
2019: 11 drugs
| Clobetasol Propionate | 32 | $5,284 | $165 |
| Fluocinonide | 55 | $4,191 | $76 |
| Fluorouracil | 37 | $3,761 | $102 |
| Triamcinolone Acetonide | 94 | $2,318 | $25 |
| Fluocinolone Acetonide | 15 | $1,602 | $107 |
| Doxycycline Hyclate | 19 | $1,470 | $77 |
| Econazole Nitrate | 13 | $1,037 | $80 |
| Clindamycin Phosphate | 20 | $705 | $35 |
| Hydroxyzine | 26 | $506 | $19 |
| Clotrimazole | 13 | $355 | $27 |
| Terbinafine | 14 | $339 | $24 |
2018: 11 drugs
| Fluocinonide | 45 | $4,079 | $91 |
| Clobetasol Propionate | 29 | $3,849 | $133 |
| Econazole Nitrate | 16 | $2,279 | $142 |
| Fluocinolone Acetonide | 17 | $2,135 | $126 |
| Triamcinolone Acetonide | 77 | $1,658 | $22 |
| Fluorouracil | 15 | $1,509 | $101 |
| Doxycycline Hyclate | 17 | $1,491 | $88 |
| Clotrimazole | 27 | $751 | $28 |
| Hydroxyzine | 16 | $335 | $21 |
| Ketoconazole | 14 | $287 | $21 |
| Hydrocortisone | 14 | $92 | $7 |
2017: 5 drugs
| Clobetasol Propionate | 22 | $5,698 | $259 |
| Fluocinonide | 62 | $5,489 | $89 |
| Mycophenolate Mofetil | 25 | $2,764 | $111 |
| Doxycycline Hyclate | 23 | $1,551 | $67 |
| Triamcinolone Acetonide | 64 | $1,376 | $21 |
2016: 12 drugs
| Fluocinonide | 54 | $5,849 | $108 |
| Mycophenolate Mofetil | 22 | $4,736 | $215 |
| Clobetasol Propionate | 23 | $3,505 | $152 |
| Doxycycline Hyclate | 30 | $2,467 | $82 |
| Hydroxychloroquine Sulfate | 11 | $2,433 | $221 |
| Triamcinolone Acetonide | 81 | $2,334 | $29 |
| Desonide | 11 | $1,455 | $132 |
| Clindamycin Phosphate | 13 | $959 | $74 |
| Ketoconazole | 22 | $669 | $30 |
| Acyclovir | 12 | $255 | $21 |
| Mupirocin | 13 | $112 | $9 |
| Hydrocortisone | 16 | $102 | $6 |
2015: 12 drugs
| Clobetasol Propionate | 46 | $9,485 | $206 |
| Fluocinonide | 58 | $5,170 | $89 |
| Desonide | 43 | $5,094 | $118 |
| Fluocinolone Acetonide | 19 | $3,671 | $193 |
| Triamcinolone Acetonide | 95 | $2,500 | $26 |
| Doxycycline Hyclate | 27 | $2,324 | $86 |
| Clindamycin Phosphate | 21 | $1,455 | $69 |
| Hydroxychloroquine Sulfate | 11 | $1,303 | $118 |
| Hydroxyzine | 13 | $439 | $34 |
| Ketoconazole | 18 | $393 | $22 |
| Valacyclovir | 15 | $323 | $22 |
| Clotrimazole | 16 | $165 | $10 |
2014: 9 drugs
| Doxycycline Hyclate | 21 | $3,946 | $188 |
| Clobetasol Propionate | 31 | $3,728 | $120 |
| Fluocinonide | 50 | $3,497 | $70 |
| Desonide | 28 | $3,220 | $115 |
| Triamcinolone Acetonide | 75 | $2,018 | $27 |
| Clindamycin Phosphate | 23 | $1,635 | $71 |
| Metronidazole | 12 | $1,615 | $135 |
| Econazole Nitrate | 21 | $937 | $45 |
| Ketoconazole | 20 | $317 | $16 |
2013: 8 drugs
| Doxycycline Hyclate | 40 | $4,652 | $116 |
| Fluocinonide | 50 | $2,750 | $55 |
| Triamcinolone Acetonide | 93 | $2,572 | $28 |
| Clindamycin Phosphate | 20 | $1,160 | $58 |
| Clobetasol Propionate | 36 | $941 | $26 |
| Fluocinolone Acetonide | 14 | $867 | $62 |
| Desonide | 11 | $853 | $78 |
| Prednisone | 19 | $113 | $6 |
Money from drug and device companies
$2,563 in 2025
| 2025 | 7 | 13 | $1,890 | $2,563 |
| 2024 | 6 | 12 | None | $559 |
| 2023 | 9 | 17 | None | $1,153 |
| 2022 | 3 | 6 | None | $314 |
| 2021 | 2 | 4 | None | $169 |
| 2020 | 1 | 1 | None | $36 |
| 2019 | 3 | 3 | None | $212 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Scientific Affairs | Tremfya | $1,930 | 2 payments
|
| Galderma Laboratories L.P. | Nemluvio | $220 | 3 payments
|
| Genzyme | Ayvakit | $190 | 3 payments
|
| Regeneron Pharmaceuticals | Dupixent | $139 | 2 payments
|
| Blueprint Medicines | Ayvakit | $35 | 1 payment
|
| Organon | Vtama | $34 | 1 payment
|
See all 13 published payments
| Genzyme | Meals · 2025-12-08 | None | $60 |
| Galderma Laboratories L.P. | Meals · 2025-11-05 | Nemluvio | $127 |
| Janssen Scientific Affairs | Consulting · 2025-10-20 | Tremfya | $1,890 |
| Galderma Laboratories L.P. | Meals · 2025-09-11 | Nemluvio | $37 |
| Regeneron Pharmaceuticals | Meals · 2025-08-27 | Dupixent | $42 |
| Genzyme | Meals · 2025-08-25 | Ayvakit | $106 |
| Galderma Laboratories L.P. | Meals · 2025-08-20 | Nemluvio | $55 |
| Incyte | Meals · 2025-08-12 | Opzelura | $15 |
| Genzyme | Meals · 2025-08-06 | Dupixent | $25 |
| Regeneron Pharmaceuticals | Meals · 2025-05-07 | Dupixent | $97 |
| Blueprint Medicines | Meals · 2025-04-23 | Ayvakit | $35 |
| Janssen Scientific Affairs | Meals · 2025-03-14 | Tremfya | $40 |
| Organon | Meals · 2025-01-08 | Vtama | $34 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $559
| Incyte | Opzelura | $174 | 2 payments
|
| Galderma Laboratories L.P. | None | $95 | 2 payments
|
| Abbvie | Rinvoq | $89 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $83 | 2 payments
|
| Genzyme | Dupixent | $79 | 3 payments
|
| Dermavant Sciences | Vtama | $39 | 1 payment
|
2023: $1,153
| Regeneron Pharmaceuticals | Dupixent | $516 | 6 payments
|
| LEO Pharma | Adbry | $209 | 3 payments
|
| Janssen Biotech | Tremfya | $125 | 1 payment
|
| Incyte | Opzelura | $83 | 2 payments
|
| Genzyme | None | $77 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $53 | 1 payment
|
| Dermavant Sciences | Vtama | $42 | 1 payment
|
| AbbVie | None | $33 | 1 payment
|
| Pfizer | Cibinqo | $15 | 1 payment
|
2022: $314
| Regeneron Pharmaceuticals | Dupixent | $140 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $120 | 3 payments
|
| Sun Pharmaceutical Industries | None | $54 | 1 payment
|
2021: $169
| Sun Pharmaceutical Industries | Ilumya | $133 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | None | $36 | 1 payment
|
2020: $36
| Sun Pharmaceutical Industries | Ilumya | $36 | 1 payment
|
2019: $212
| Galderma Laboratories L.P. | Epiduo Forte | $109 | 1 payment
|
| Ortho Dermatologics a division of Bausch Health US | None | $77 | 1 payment
|
| Sun Pharmaceutical Industries | Ilumya | $25 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| E.R. Squibb & Sons, L.L.C. · Correction of Psoriatic Skin-Resident Memory T Cell Signatures By Deucravacitinib · 2025 | Their institution | $735,840 |
| Regeneron Pharmaceuticals, Inc. · Spatial Molecular Signatures of Cutaneous Dupilumab Response · 2023 | Their institution | $308,604 |
| E.R. Squibb & Sons, L.L.C. · Correction of Psoriatic Skin-Resident Memory T Cell Signatures By Deucravacitinib · 2023 | Their institution | $156,822 |
| Regeneron Pharmaceuticals, Inc. · Spatial Molecular Signatures of Cutaneous Dupilumab Response · 2024 | Their institution | $51,572 |
| Regeneron Pharmaceuticals, Inc. · Spatial Molecular Signatures of Cutaneous Dupilumab Response · 2022 | Their institution | $38,846 |
| Regeneron Pharmaceuticals, Inc. · Spatial Molecular Signatures of Cutaneous Dupilumab Response · 2025 | Their institution | $33,149 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 74.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1790999175
- Licence
- CA 96916California A96916: Current · expires 2028-04-30
- Trained
- Stanford University School of Medicine, 2005 · 21 years ago
- Group
- University of California San Francisco · UCSF Medical Group Business Services
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 1701 Divisadero St, 3rd Floor, Dept of Dermatology, San Francisco, CA, 94115
- NPI first listed
- 2007-05-09
- NPI last updated
- 2007-07-08
This is when the NPI record was last certified, not a medical board exam.